INTRODUCTION
Numerous studies have identified that hemostasis is perturbed in patients with hemolytic anemias including sickle cell disease (SCD). Hemostatic abnormalities observed in SCD include evidence for enhanced thrombin generation [1] , increased circulatory levels of tissue factor (TF) antigen and procoagulant activity [2, 3] , and circulating endothelial cells and endothelial-and monocyte-derived microparticles that are positive for TF [4, 5] . TF, a cell surface receptor for factor-VII/VIIa, is the physiologic initiator of blood coagulation, forming a complex with circulating factor-VIIa, activating factor-X with subsequent thrombin generation [6] . Although TF is not constitutively expressed on endothelium or monocytes in vivo, its expression can be induced by a variety of agonists with pathophysiologic relevance to hemolytic anemias including the inflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α), hypoxia, shear stress, growth factors, endotoxin and reperfusion injury [7] [8] [9] .
Erythrocytes, that undergo hemolysis intravascularly, release heme and hemoglobin into the circulation with documented studies suggesting that both heme and cell-free hemoglobin may modulate disease severity in patients with SCD by decreasing the bio-availability of the cyto-protective mediator nitric oxide (NO) [10] [11] [12] . Other studies have shown that heme can activate endothelial cells in vitro, up-regulating the expression of surface adhesion molecules such as VCAM-1, ICAM-1 and E-selectin [13] . Since many cytokine-induced down-stream signaling events in endothelial cells are common to both TF induction and adhesion molecule expression, we hypothesized that heme could affect hemostasis by modulating endothelial TF expression. We report that heme at pathologically relevant concentrations induces TF mRNA and protein in 5 endothelial cells. We show that TF produced in response to heme is expressed on the cell surface, and that it is functional.
MATERIALS and METHODS

Materials:
Three TF-specific antibodies including a rabbit polyclonal and two mouse monoclonal (clones hTF-1 and TF9-10H10) antibodies were used in this study. The rabbit polyclonal antibody and the mouse monoclonal antibody hTF-1 were kindly provided by Dr Ronald Bach (VA Medical Center, Minneapolis, MN), and the clone TF9-10H10 was obtained from Calbiochem (La Jolla, CA). Details of these antibodies and other reagents used are described in the Supplementary Section.
Culture of Endothelial Cells and THP-1 Cells:
Human umbilical vein endothelial cells (HUVECs) were obtained from Clonetics (Lonza, Walkersville, MD) and cultured according to the manufacturer's protocol. Cells at passages 2 to 4 were used. All experiments were performed using endothelial growth medium containing 50µg/ml polymyxin-B (EGM-polyB), unless otherwise indicated. Representative experiments also were performed using human lung microvascular endothelial cells (HLMECs, passages 2 to 4) from Clonetics. Endothelial cells were incubated in the absence or presence of the desired agonist (1-100µM heme, 10ng/ml IL-1α, or 10ng/ml TNF-α) for various times (0.5-8 hours), and then analyzed for TF mRNA, TF protein or TF procoagulant activity.
As a positive control for inducible TF expression, we used THP-1 cells (a human monocytic leukemia cell line, ATCC, Manassas, VA), activated with LPS in the absence of polymyxin-B.
Preparation of Heme:
Fresh working stocks of 10mM heme were prepared in 0.05N NaOH, diluted to desired concentration in EGM-polyB, and pH adjusted to 7.4.
Endotoxin-free water was used in the preparation of all reagents. Endotoxin levels in reagents and media were assessed using a limulus assay kit (Lonza, Wakersville, MD).
Analysis of Endothelial TF Protein: Cell surface TF expression was assessed using two complementary methods including an ELISA-based assay (intact cell monolayer) and flow cytometry (cell suspension) as previously described for endothelial adhesion receptors [14] . Total TF protein level was assessed using Western blotting of cellular proteins. While the monoclonal anti-TF antibodies, TF9-10H10 and hTF-1, were used in ELISA and/or flow cytometry procedures, the rabbit polyclonal anti-TF antibody was employed in Western analysis (for details refer to supplementary section). TF Functional Activity: TF procoagulant activity on intact endothelial monolayers or in cell lysates prepared from control and treated cultures were measured using a TF activity assay kit (American Diagnostica, Stanford, CT). To confirm that the conversion of factor-X to factor-Xa was TF-mediated, in parallel experiments either the cell monolayers (~50,000 cells) or endothelial lysates (2.5µg protein) were pre-incubated with the monoclonal anti-TF antibody hTF-1 (15µg) for 30-minutes, and assayed for TF activity.
Analysis of Endothelial
Statistical analysis: Statistical evaluation was performed using Sigmastat (Jandel, San Rafael, CA). All values presented are mean±SD. Multiple group comparison was done using either one-way ANOVA or the Kruskal-Wallis test, as appropriate, and if significant, group-wise comparisons were performed with the Bonferroni or the Dunn's test. Differences at P<0.05 were considered statistically significant. Paired-group comparison was performed using either the paired t-test, or the Mann-Whitney rank sum test, as appropriate. 
RESULTS
Effects of Heme on Endothelial
Effects of Heme on Endothelial TF mRNA Expression:
In preliminary experiments we found that heme induced TF mRNA expression in a concentration- Effects of polymyxin-B on LPS-, heme-, and IL-1α-induced endothelial TF expression were evaluated. While polymyxin-B had no inhibitory effect on either heme-, or IL-1α-induced endothelial TF expression, LPS (1µg/ml)-induced TF mRNA expression was inhibited by 86% (supplementary Figure-S1 ). In addition, heme used in our experiments was free of any detectable endotoxin as assessed by the limulus assay (<0.01EU/ml in test medium containing 100µM heme). of procoagulant activity with all three agonists (heme, TNF-α, and IL-1α)-treated cells was specifically TF-associated. Since TF procoagulant activity in cell lysates measures total cellular activity including cell surface, encrypted and intracellular TF, we further evaluated whether heme induces the expression of functional procoagulant TF on intact endothelium. Results demonstrate that both heme and cytokines induced cell surface TF procoagulant activity with 2.6-, 7.2-, and 11.9-fold increases noted over media control ( Figure-3C ). Measured surface procoagulant activity was, however <10% of the total activity in both heme-and cytokine-activated endothelial cells ( Figures-3B and 3C ).
Effects of Heme on
Effects of Curcumin and Sulfasalzine on Heme-Induced TF mRNA Expression:
In an attempt to assess whether the transcription factor NFκB was involved in mediating heme-induced TF expression, we evaluated the effects of inhibitors of NFκB activation including sulfasalazine and curcumin [15, 16] . 
DISCUSSION
We explored the possibility that heme, a product of intravascular hemolysis in patients with hemolytic anemias, could modulate hemostasis by an effect on endothelial TF expression. Our results demonstrate that heme, at pathologically relevant concentrations, induces TF expression (both message and protein) in endothelial cells, and that it is biologically active.
TF, a 47-kDa transmembrane glycoprotein, the cellular receptor and cofactor for coagulation factor-VII/VIIa, and the predominant initiator of blood coagulation [6] , can be expressed on activated monocytes and endothelial cells [7] . Expression on the endothelium can be induced by a variety of agonists including inflammatory cytokines IL-1 and TNF-α [7] . While multiple nuclear transcription factors are involved in TF induction in endothelial cells, the agonists IL-1α and TNF-α mediate their effects through activation of AP-1 and NFκB [7, 17] . [15, 16] , and curcumin, in addition, may affect activation of AP-1, Egr-1 and SP-1 [16] . In preliminary experiments we further assessed whether heme-induced TF expression was modulated by sulfasalazine and curcumin. Both modulators blocked heme-induced TF mRNA expression (Figure-4) suggesting that NFκB is one of the transcription factors involved in mediating the observed heme-effects. In this context it is interesting to note that a recent study by Hasan and Schafer has demonstrated that induction of Egr-1 expression by heme caused TF expression in vascular smooth muscle cells [19] . Using flow cytometry and ELISA, we also show that heme induces cell surface expression of TF antigen on both macro-, and micro-vascular endothelial cells ( Figures-1A and 1B) , and that the cell surface expression of TF by heme was comparable to that induced by TNF-α ( Figures-1C and 1D ). Since plasma heme levels in patients with intravascular hemolytic anemia such as SCD and paroxysmal nocturnal hemoglobinuria (PNH) have been documented to range between 20µM and 600µM [10, 20] , and since significant changes in TF expression reported here were noted at heme concentrations as low as 1µM, the heme-effects observed in our study appear to be pathologically relevant. In addition, relevance may also be extended to situations associated with acute elevations in levels of plasma hemoglobin such as cardiopulmonary bypass. These conditions carry an increased thrombotic risk [20] [21] [22] .
Since endotoxin can induce TF expression in endothelial cells even at very low concentrations, use of endotoxin-free reagents and media in our experiments was crucial to delineate the heme-effect. Previous studies have shown that polymyxin-B inhibits endotoxin-induced cell-activation including TF expression in human aortic endothelial cells [23] . We have therefore performed all studies in media containing polymyxin-B. In addition, in preliminary experiments we evaluated the effects of polymyxin-B on agonist-induced TF expression, and confirmed that this agent blocked LPS-mediated, but not heme-or cytokine-induced, TF expression in HUVECs (Figure-S1 ). Moreover, limulus assay on the media used in our studies was noted to be free of Gladwin and coworkers have documented that intravascular hemolysis produces a state of resistance to endogenously produced, or exogenously delivered NO, due to the stoichiometric oxidation of endogenous NO by cell-free plasma hemoglobin with resultant inhibition of vasodilatation [11] . 
